In a shift toward more convenient cancer care, the United States Food and Drug Administration approved Sanofi’s Sarclisa Escena, a subcutaneous version of its multiple myeloma medicine Sarclisa, as the first anticancer therapy cleared for use with a wearable portable injector.
The decision moves treatment beyond the infusion chair: instead of lengthy intravenous dosing, patients can receive the drug via a device that delivers it under the skin, potentially shortening clinic time and easing pressure on oncology infusion capacity. It also strengthens Sanofi’s hand in the competitive multiple myeloma arena, where faster, simpler administration can influence physician choice and patient adherence. How broadly this changes practice will hinge on label specifics, site-of-care policies, and whether insurers support home or outpatient use of the device.
The next signals to watch are the speed of the United States rollout, pricing and reimbursement decisions, and early uptake among treatment centers. Any post-approval study requirements, safety updates, or expansion into additional patient groups will indicate how far this delivery innovation can reshape routine cancer dosing.
For more detail, read the full announcement.